Chemical Structure Of Remibrutinib (Rhapsido 01)
Rhapsido Tablet
Product Images NDC 0078-1483
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Rhapsido (NDC 0078-1483). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 Mean Change From Baseline In Weekly Itch Severity Score (iss7) And Hive Severity Score (hss7) Up To Week 24 In Remix-2 (observed Data) (Rhapsido 02)
This text provides information on the mean change +/- standard error (SE) for two different groups at specific time points during a study comparing a treatment (RFAPSIDG 25mg bid) with a placebo. The study included 257 participants in the treatment group and 153 participants in the placebo group.*
Principal Display Panel Ndc 0078-1483-20 Rhapsido® (remibrutinib) Tablets 25 mg Per Tablet Swallow Tablets Whole With Water. Do Not Split, Crush, Or Chew Tablets. Rx Only 60 Tablets Novartis (Rhapsido 03)
This is a label for Rhapsido tablets containing remibrutinib. It provides instructions to store the tablets between 15°C and 30°C (59°F to 86°F) and to protect them from moisture. The tablets should be swallowed whole with water and should not be crushed. The label indicates it is produced by NOVARTIS.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
